The objective of this study is to validate the diagnostic performance and practical feasibility of massively parallel
genomic sequencing for the non-invasive prenatal assessment of trisomy 21 in a large number of pregnancies that have
undergone conventional screening and were clinically indicated for definitive
testing by amniocentesis or chorionic villus sampling.
10/6/16 — Cleveland Clinic
Genomic Medicine Institute Founding Chair and Director of Center for Personalized Genetic Healthcare, Charis Eng, MD, PhD was quoted in the article, «Who should
undergo genetic
testing for breast cancer?»